SOURCE:
The study, led by Vikas Ostwal, DM, Tata Memorial Centre, Mumbai, India, was published online in JAMA Network Open.
LIMITATIONS:
The lack of a placebo group could affect the interpretation of the results. The study evaluated only a 10-mg dose of olanzapine but did not consider a lower (5-mg) dose. Other potential side effects of olanzapine, such as increased appetite or constipation, were not reported. The study predominantly involved patients with gastrointestinal cancers receiving oxaliplatin-containing regimens, which may limit the generalizability of the findings.
DISCLOSURES:
The study was supported by grants from Intas Pharmaceuticals, Zydus Lifesciences, and Dr. Reddy’s Laboratories to Tata Memorial Centre. Several authors reported receiving grants and having other ties with various sources.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.